Elexacaftor/ivacaftor/tezacaftor (Trikafta, Vertex Pharmaceuticals) is indicated for patients aged 12 years and older with cystic fibrosis who have at least 1 F508del mutation.
Ustekinumab both induced and maintained clinical remission in a significantly greater proportion of adult patients with moderately to severely active ulcerative colitis compared with placebo.
Top news of the day from across the health care landscape.
Research explores why patients with mutated KRAS genes in tumor cells are sensitive to cetuximab.
Limited supply of chemotherapy agent that treats several pediatric cancers may lead to rationing of doses.
Ravulizumab-cwvz (Ultomiris, Alexion) is indicated to inhibit complement-mediated thrombotic microangiopathy in adult and pediatric patients with atypical hemolytic uremic syndrome.
The open-label Phase 2 trial looked to expand treatment for patients with newly diagnosed and persistent immune thrombocytopenia.
Top news of the day from across the health care landscape.
After participating in a sleep-education program, 41% of participants who survived cancer had their insomnia successfully treated.
Top news of the week from Specialty Pharmacy Times.
Pending results of the California Practice Standards and Jurisprudence Exam (CPJE) have been invalidated for 1400 applicants that recently took the test, due to a cheating issue.
Abrocitinib showed improvements in skin clearance and itch relief in patients aged 12 years and older with moderate-to-severe atopic dermatitis.
Glenmark Pharmaceuticals has received FDA approval for abiraterone acetate tablets USP, 250 mg, a generic of Janssen's Zytiga tablets, 250 mg.1
Study suggests that blocking a signaling pathway that includes the inflammatory factor CXCL10-CXCR3 may prevent brain metastasis.
Top news of the day from across the health care landscape.
Nine widely-used medications have experienced substantial price growth since 2016, adding $5.1 billion to overall drug spending.
The full-day meeting will feature recognized experts sharing the latest clinical data in oncology, while exploring best practices and management strategies.
Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.
The International Society of Oncology Pharmacy Practitioners global position on oncology biosimilar use covers regulation and evaluation, implementation, education, and monitoring.
Top news of the day from across the health care landscape.
Expanded access to direct-acting antiviral drugs are vital to achieve elimination targets set by the World Health Organization for hepatitis C virus infections.
The Pharmacy Technician Certification Board (PTCB) has launched 2 specialty areas of Assessment-Based Certificate Programs: Technician Product Verification (TPV) and Medication History.
Top news of the day from across the health care landscape.
In the wake of California’s drug transparency law, an analysis by state health officials on pricing trends found that drug companies raised the whole acquisition cost dramatically for many drugs.
A report by the Institute for Clinical and Economic Review lists the top drugs with the greatest price increases not supported by new clinical evidence.
New study provides evidence that the use of antiretroviral therapy alters the formation or stabilization of HIV latent reservoirs.
Top news of the day from across the health care landscape.
Lasmiditan (Reyvow, Eli Lilly) resolved pain and most bothersome symptoms within 2 hours of treatment in patients with migraine.
Top news of the week from Specialty Pharmacy Times.
This article is the third in a series on difficult to pronounce drug names.
